Myeloproliferative Disorders
3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BiocorpSB939
Eli Lilly and CompanyLY2784544
ExelixisXL019
Clinical Trials (3)
Total enrollment: 203 patients across 3 trials
Study of SB939 in Subjects With Myelofibrosis
Start: Nov 2010Est. completion: Nov 201223 patients
Phase 2Completed
A Study in Myeloproliferative Disorders
Start: Apr 2010Est. completion: Feb 201880 patients
Phase 1Completed
A Safety Study of XL019 in Adults With Myelofibrosis
Start: Aug 2007100 patients
Phase 1Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.